GlaxoSmithKline said the FDA approved its Veramyst Nasal spray for treating allergy symptoms in adults and children over 2 years old, marking the first regulatory approval of fluticasone furoate nasal spray. The company said Veramyst would be available by prescription in the U.S. by late May and is being considered for approval in Europe, Japan, Canada and Australia.

Full Story:

Related Summaries